Does LUTETIUM LU-177 Cause Malignant neoplasm progression? 39 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 39 reports of Malignant neoplasm progression have been filed in association with LUTETIUM LU-177. This represents 34.2% of all adverse event reports for LUTETIUM LU-177.
39
Reports of Malignant neoplasm progression with LUTETIUM LU-177
34.2%
of all LUTETIUM LU-177 reports
6
Deaths
21
Hospitalizations
How Dangerous Is Malignant neoplasm progression From LUTETIUM LU-177?
Of the 39 reports, 6 (15.4%) resulted in death, 21 (53.8%) required hospitalization, and 3 (7.7%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for LUTETIUM LU-177. However, 39 reports have been filed with the FAERS database.
What Other Side Effects Does LUTETIUM LU-177 Cause?
Fatigue (35)
Diarrhoea (29)
Abdominal pain (19)
Asthenia (19)
Vomiting (19)
Blood pressure increased (18)
Body temperature decreased (18)
Drug ineffective (18)
Blood pressure systolic increased (17)
Nausea (17)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which LUTETIUM LU-177 Alternatives Have Lower Malignant neoplasm progression Risk?
LUTETIUM LU-177 vs LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN
LUTETIUM LU-177 vs LUTETIUM OXODOTREOTIDE LU-177
LUTETIUM LU-177 vs LUTROPIN ALFA
LUTETIUM LU-177 vs LYMECYCLINE
LUTETIUM LU-177 vs LYRICA